

## NCIC CLINICAL TRIALS GROUP

## LUNG

DISEASE SITE COMMITTEE MEETING AGENDA

DELTA CHELSEA HOTEL, TORONTO

**ROOM: CHURCHILL A**SATURDAY APRIL 27<sup>TH</sup>, 2013

1:30 – 4:15 PM, EST

CHAIRS: G. GOSS / Y. UNG

Objectives:

To summarize recent developments in the understanding of molecular biology and therapeutics as these relate to the management of lung cancer

To cite and analyze recent results of lung cancer clinical studies conducted by or in collaboration with NCIC Clinical Trials Group

---

1:30 – 1:40 pm     **Welcome and Review of the year**     **G. Goss/Y. Ung**

1:40 – 2:30 pm     **Report from Study Chairs: Update on Current Trials**

BR.26:

A Double Blind Placebo Controlled Randomized Trial Of  
PF-804 In Patients With Incurable Stage IIIB/IV Non-Small Cell  
Lung Cancer After Failure Of Standard Therapy For Advanced  
Or Metastatic Disease

**P. Ellis**BRC.2/BRC.2E:

A Phase III Randomized Trial Of Adjuvant Chemotherapy With Or  
Without Bevacizumab For Patients With Completely Resected Stage  
IB (> 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC) /

**C. Butts**

A Prospective Economic Analysis Of NCIC CTG BRC.2/E1505

BRC.5:

A Phase III Randomized Trial Of Lobectomy Versus Sublobar  
Resection For Small (< 2cm) Peripheral Non-Small Cell Lung Cancer

**J. Deslauriers**BR.28:

Concurrent Once-Daily Versus Twice-Daily Radiotherapy: A 2-Arm  
Randomised Controlled Trial Of Concurrent Chemo-Radiotherapy Comparing  
Twice-Daily And Once-Daily Radiotherapy Schedules In Patients With Limited  
Stage Small Cell Lung Cancer (SCLC) And Good Performance Status

**A. Bezjak**

**IND.207:**

A Phase II Study Of PF-03446962 In Patients With Advanced Malignant Pleural Mesothelioma

**Q. Chu****IND.211:**

A Randomized Phase II Study Of Reolysin In Patients With Previously Treated Advanced Or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy

**D. Morris****IND.215:**

A Phase Ib Study Of Selumetinib In Patients With Previously Treated Or Untreated Advanced/Metastatic Nsclc Who Are Receiving Standard Chemotherapy Regimen

**G. Nicholas**

2:30 – 2:40 pm    **BREAK**

2:40 – 4:00 pm    **New Concepts and Proposals**

- NSCLC
- Small cell lung cancer

**G. Goss/Y. Ung**

4.00 – 4:15 pm    **Summary and Close**

**G. Goss/Y. Ung**